Cost drivers in the pharmacological treatment of interstitial lung disease

INTRODUCTION: Treatments of interstitial lung diseases (ILDs) mainly focus on disease stabilization and relief of symptoms by managing inflammation or suppressing fibrosis by (in part costly) drugs. To highlight economic burden of drug treatment in different ILD-subtypes we assessed cost trends and...

Descripción completa

Detalles Bibliográficos
Autores principales: Maqhuzu, Phillen Nozibuyiso, Kreuter, Michael, Bahmer, Thomas, Kahn, Nicolas, Claussen, Martin, Holle, Rolf, Schwarzkopf, Larissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335870/
https://www.ncbi.nlm.nih.gov/pubmed/34344376
http://dx.doi.org/10.1186/s12931-021-01807-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335870/
https://www.ncbi.nlm.nih.gov/pubmed/34344376
http://dx.doi.org/10.1186/s12931-021-01807-8

Ejemplares similares